Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
103.35
(
-1.03%
)
Bitcoin
70,180.29
(
0.40%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 104041

Sunday, 10/31/2010 10:35:49 PM

Sunday, October 31, 2010 10:35:49 PM

Post# of 257262
MRK reports that 44% and 46% of patients in the Boceprevir SPRINT-2 and RESPOND-2 studies, respectively, stopped treatment early according to the response-guided protocol in these studies:

http://finance.yahoo.com/news/Mercks-Investigational-bw-1755524465.html?x=0&.v=1

Early response-guided stopping occurred after 28 weeks in the SPRINT-2 study in the first-line setting (which included a 4-week lead-in period on SoC only) and after 36 weeks in the RESPOND-2 study in the second-line (for non-null-responders in the first line).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now